{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014822","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.185695+00:00","generated_at":"2026-05-15T07:49:09.016448+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Palisade Bio signs enrollment deal with Iterative Health, issues $3M stock to affiliate","bullets":["Entered MSA with Iterative Health to assist with patient enrollment for Phase 2 study of PALI-2108 in ulcerative colitis.","Issued 1,536,885 shares at $1.952/share (5-day VWAP) for total $3.0 million to an affiliate of Iterative Health.","Funds support accelerated enrollment; shares sold in private placement exempt from registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014822","json":"https://secwatch.observer/filing/0001493152-26-014822.json","markdown":"https://secwatch.observer/filing/0001493152-26-014822.md","text":"https://secwatch.observer/filing/0001493152-26-014822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315226014822/0001493152-26-014822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315226014822/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:49:09.016448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}